Howard N. Langstein - 01 Mar 2026 Form 3 Insider Report for TELA Bio, Inc. (TELA)

Role
Chief Medical Officer
Signature
/s/ Megan Smeykal, Attorney-in-Fact
Issuer symbol
TELA
Transactions as of
01 Mar 2026
Net transactions value
$0
Form type
3
Filing time
11 Mar 2026, 16:05:01 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Langstein Howard N. Chief Medical Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN /s/ Megan Smeykal, Attorney-in-Fact 11 Mar 2026 0002117151

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TELA Common Stock 71,347 01 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TELA Stock Option (Right to Buy) 01 Mar 2026 Common Stock 72,750 $0.7830 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests 25% on February 18, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service through the applicable vesting dates.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney